{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Multi+Center&page=59",
    "query": {
      "condition": "Multi Center",
      "page": 59
    },
    "page_size": 10
  },
  "pagination": {
    "page": 59,
    "page_size": 10,
    "total_count": 6600,
    "total_pages": 660,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Multi+Center&page=60&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Multi+Center&page=58&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-11-08T22:52:47.554Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT02579382",
      "title": "Study to Evaluate the Safety, Tolerability, and Efficacy of Vesatolimod in Combination With Tenofovir Disoproxil Fumarate (TDF) in Adults With Chronic Hepatitis B (CHB) Infection Who Are Currently Not Being Treated",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Chronic Hepatitis B"
      ],
      "interventions": [
        {
          "name": "TDF",
          "type": "DRUG"
        },
        {
          "name": "Vesatolimod",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Gilead Sciences",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 192,
      "start_date": "2015-11-10",
      "completion_date": "2019-05-03",
      "has_results": true,
      "last_update_posted_date": "2020-05-18",
      "last_synced_at": "2026-11-08T22:52:47.554Z",
      "location_count": 9,
      "location_summary": "Los Angeles, California • Palo Alto, California • San Diego, California + 6 more",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Palo Alto",
          "state": "California"
        },
        {
          "city": "San Diego",
          "state": "California"
        },
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "Honolulu",
          "state": "Hawaii"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02579382"
    },
    {
      "nct_id": "NCT01421524",
      "title": "Study of CC-122 to Evaluate the Safety, Tolerability, and Effectiveness for Patients With Advanced Solid Tumors, Non-Hodgkin's Lymphoma, or Multiple Myeloma",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Multiple Myeloma",
        "Lymphoma, Large B-Cell, Diffuse",
        "Pleiotropic Pathway Modifier",
        "Glioblastoma",
        "Lymphoma",
        "Primary Central Nervous System Lymphoma"
      ],
      "interventions": [
        {
          "name": "CC-122",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Celgene",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 271,
      "start_date": "2011-09-12",
      "completion_date": "2023-11-21",
      "has_results": false,
      "last_update_posted_date": "2023-12-12",
      "last_synced_at": "2026-11-08T22:52:47.554Z",
      "location_count": 17,
      "location_summary": "Duarte, California • Los Angeles, California • San Francisco, California + 13 more",
      "locations": [
        {
          "city": "Duarte",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "Ann Arbor",
          "state": "Michigan"
        },
        {
          "city": "Detroit",
          "state": "Michigan"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01421524"
    },
    {
      "nct_id": "NCT02299362",
      "title": "The Treatment of Progressive Early Onset Spinal Deformities: A Multi-Center Outcome Study",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Early Onset Scoliosis",
        "Congenital Spinal Deformities",
        "Infantile Idiopathic Scoliosis",
        "Neuromuscular Spinal Deformity",
        "Syndromic Spinal Deformity",
        "Thoracic Insufficiency Syndrome"
      ],
      "interventions": [],
      "intervention_types": [],
      "sponsor": "Growing Spine Study Group",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "1 Day",
        "maximum_age": "18 Years",
        "sex": "ALL",
        "summary": "1 Day to 18 Years"
      },
      "enrollment_count": 2602,
      "start_date": "2008-10",
      "completion_date": "2020-02-04",
      "has_results": false,
      "last_update_posted_date": "2020-02-06",
      "last_synced_at": "2026-11-08T22:52:47.554Z",
      "location_count": 19,
      "location_summary": "Little Rock, Arkansas • Los Angeles, California • San Diego, California + 16 more",
      "locations": [
        {
          "city": "Little Rock",
          "state": "Arkansas"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "San Diego",
          "state": "California"
        },
        {
          "city": "Wilmington",
          "state": "Delaware"
        },
        {
          "city": "Washington D.C.",
          "state": "District of Columbia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02299362"
    },
    {
      "nct_id": "NCT03893240",
      "title": "Neutralizing Antibody Seroprevalence Study With a Retrospective Component in Participants With Late-Onset Pompe Disease",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Pompe Disease",
        "Pompe Disease (Late-onset)",
        "Glycogen Storage Disease Type 2",
        "LOPD",
        "Lysosomal Storage Diseases",
        "Acid Maltase Deficiency"
      ],
      "interventions": [
        {
          "name": "Neutralizing Antibody to SPK-3006 capsid",
          "type": "DIAGNOSTIC_TEST"
        }
      ],
      "intervention_types": [
        "DIAGNOSTIC_TEST"
      ],
      "sponsor": "Spark Therapeutics, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 61,
      "start_date": "2019-06-12",
      "completion_date": "2020-10-27",
      "has_results": false,
      "last_update_posted_date": "2023-03-24",
      "last_synced_at": "2026-11-08T22:52:47.554Z",
      "location_count": 6,
      "location_summary": "Phoenix, Arizona • Orange, California • Kansas City, Kansas + 3 more",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Orange",
          "state": "California"
        },
        {
          "city": "Kansas City",
          "state": "Kansas"
        },
        {
          "city": "Minneapolis",
          "state": "Minnesota"
        },
        {
          "city": "Portland",
          "state": "Oregon"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03893240"
    },
    {
      "nct_id": "NCT02282020",
      "title": "Olaparib Treatment in Relapsed Germline Breast Cancer Susceptibility Gene (BRCA) Mutated Ovarian Cancer Patients Who Have Progressed at Least 6 Months After Last Platinum Treatment and Have Received at Least 2 Prior Platinum Treatments",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Relapsed Ovarian Cancer, BRCA Mutation, Platinum Sensitivity"
      ],
      "interventions": [
        {
          "name": "OLAPARIB",
          "type": "DRUG"
        },
        {
          "name": "Single agent chemotherapy",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "AstraZeneca",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "130 Years",
        "sex": "FEMALE",
        "summary": "18 Years to 130 Years · Female only"
      },
      "enrollment_count": 266,
      "start_date": "2015-02-06",
      "completion_date": "2022-07-19",
      "has_results": true,
      "last_update_posted_date": "2022-07-26",
      "last_synced_at": "2026-11-08T22:52:47.554Z",
      "location_count": 22,
      "location_summary": "Birmingham, Alabama • Mobile, Alabama • Sacramento, California + 19 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Mobile",
          "state": "Alabama"
        },
        {
          "city": "Sacramento",
          "state": "California"
        },
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "Aurora",
          "state": "Colorado"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02282020"
    },
    {
      "nct_id": "NCT00600496",
      "title": "A Phase I, Open-Label, Multi-center Study to Assess the Safety, Tolerability and Pharmacokinetics of AZD6244 (ARRY-142886)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Breast Cancer",
        "Breast Neoplasms",
        "Colon Cancer",
        "Colonic Cancer",
        "Colon Neoplasms",
        "Lung Cancer",
        "Melanoma",
        "Kidney Cancer"
      ],
      "interventions": [
        {
          "name": "AZD6244",
          "type": "DRUG"
        },
        {
          "name": "Dacarbazine",
          "type": "DRUG"
        },
        {
          "name": "Erlotinib",
          "type": "DRUG"
        },
        {
          "name": "Docetaxel",
          "type": "DRUG"
        },
        {
          "name": "Temsirolimus",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "AstraZeneca",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "130 Years",
        "sex": "ALL",
        "summary": "18 Years to 130 Years"
      },
      "enrollment_count": 140,
      "start_date": "2007-12-14",
      "completion_date": "2025-12-18",
      "has_results": false,
      "last_update_posted_date": "2026-05-27",
      "last_synced_at": "2026-11-08T22:52:47.554Z",
      "location_count": 4,
      "location_summary": "Detroit, Michigan • Philadelphia, Pennsylvania • Nashville, Tennessee + 1 more",
      "locations": [
        {
          "city": "Detroit",
          "state": "Michigan"
        },
        {
          "city": "Philadelphia",
          "state": "Pennsylvania"
        },
        {
          "city": "Nashville",
          "state": "Tennessee"
        },
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00600496"
    },
    {
      "nct_id": "NCT04646603",
      "title": "MRG-001 as an Immunoregulatory and Regenerative Therapy for COVID-19 Patients",
      "overall_status": "UNKNOWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "COVID-19",
        "ARDS, Human",
        "Stem Cells",
        "Regeneration"
      ],
      "interventions": [
        {
          "name": "MRG-001",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "MedRegen LLC",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 40,
      "start_date": "2021-12-01",
      "completion_date": "2022-07-01",
      "has_results": false,
      "last_update_posted_date": "2022-02-15",
      "last_synced_at": "2026-11-08T22:52:47.554Z",
      "location_count": 1,
      "location_summary": "Baltimore, Maryland",
      "locations": [
        {
          "city": "Baltimore",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04646603"
    },
    {
      "nct_id": "NCT02267642",
      "title": "A Phase II Study Evaluating the Efficacy and Safety of AbGn-168H in Patients With Active Psoriatic Arthritis",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Psoriatic Arthritis"
      ],
      "interventions": [
        {
          "name": "AbGn-168H",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "AbGenomics B.V Taiwan Branch",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "18 Years to 75 Years"
      },
      "enrollment_count": 20,
      "start_date": "2015-01",
      "completion_date": "2016-01",
      "has_results": false,
      "last_update_posted_date": "2017-01-24",
      "last_synced_at": "2026-11-08T22:52:47.554Z",
      "location_count": 7,
      "location_summary": "La Jolla, California • Palo Alto, California • Sarasota, Florida + 4 more",
      "locations": [
        {
          "city": "La Jolla",
          "state": "California"
        },
        {
          "city": "Palo Alto",
          "state": "California"
        },
        {
          "city": "Sarasota",
          "state": "Florida"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "Lansing",
          "state": "Michigan"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02267642"
    },
    {
      "nct_id": "NCT01522170",
      "title": "aHUS Observational Long Term Follow-Up",
      "overall_status": "TERMINATED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Atypical Hemolytic Uremic Syndrome"
      ],
      "interventions": [],
      "intervention_types": [],
      "sponsor": "Alexion Pharmaceuticals, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": null,
        "sex": "ALL",
        "summary": "Not listed"
      },
      "enrollment_count": 94,
      "start_date": "2012-03",
      "completion_date": "2017-01",
      "has_results": false,
      "last_update_posted_date": "2017-02-24",
      "last_synced_at": "2026-11-08T22:52:47.554Z",
      "location_count": 16,
      "location_summary": "Atlanta, Georgia • Dunwoody, Georgia • Fort Wayne, Indiana + 12 more",
      "locations": [
        {
          "city": "Atlanta",
          "state": "Georgia"
        },
        {
          "city": "Dunwoody",
          "state": "Georgia"
        },
        {
          "city": "Fort Wayne",
          "state": "Indiana"
        },
        {
          "city": "Fort Wayne",
          "state": "Indiana"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01522170"
    },
    {
      "nct_id": "NCT00724841",
      "title": "A Phase I/II Study of GMX1777 in Combination With Temozolomide for the Treatment of Metastatic Melanoma",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Metastatic Melanoma"
      ],
      "interventions": [
        {
          "name": "Obatoclax Mesylate",
          "type": "DRUG"
        },
        {
          "name": "Temozolomide",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Gemin X",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 1,
      "start_date": "2008-06",
      "completion_date": "2010-08",
      "has_results": false,
      "last_update_posted_date": "2016-07-22",
      "last_synced_at": "2026-11-08T22:52:47.554Z",
      "location_count": 1,
      "location_summary": "Philadelphia, Pennsylvania",
      "locations": [
        {
          "city": "Philadelphia",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00724841"
    }
  ]
}